Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22916019 | 0.92 | KDM4E (0.41) | KDM4EALDH1A1GAATDP1TSHR | |
| SCHEMBL22916012 | 0.89 | ALDH1A1 (0.53) | ALDH1A1 | |
| SCHEMBL22915934 | 0.88 | HPGD (0.51) | ALDH1A1GAANAMPTNPC1 | |
| SCHEMBL22915968 | 0.82 | MAPK1 (0.60) | KDM4EALDH1A1GAANAMPTTP53 | |
| SCHEMBL24062105 | 0.81 | NAMPT (0.44) | KDM4ENAMPTSMN1; SMN2 | |
| SCHEMBL20213867 | 0.80 | CDK4 (0.56) | ALDH1A1NAMPT | |
| SCHEMBL22915972 | 0.80 | NAMPT (0.48) | KDM4EALDH1A1NAMPTSMN1; SMN2 | |
| SCHEMBL22915904 | 0.80 | NAMPT (0.49) | KDM4ENAMPTNPC1RAB9APKM | |
| SCHEMBL22916015 | 0.79 | POLB (0.57) | KDM4EALDH1A1TSHRNAMPTTP53 | |
| SCHEMBL22915942 | 0.79 | GRM5 (0.50) | KDM4EALDH1A1NAMPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186572-B2 | Bacterial glutaminyl cyclases and inhibitors thereof for use in the treatment of periodontitis | FRAUNHOFER-GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (DE) | 2021-11-30 | — | — | US | disclosed |
| EP-3548613-B1 | BACTERIAL GLUTAMINYL CYCLASE INHIBITORS AND USE THEREOF IN THE TREATMENT OF PERIODONTITIS | FRAUNHOFER GES FORSCHUNG (DE) | 2021-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11186572-B2 | Bacterial glutaminyl cyclases and inhibitors thereof for use in the treatment of periodontitis | GMPS, QPCT, GLS | KDM4E 2159/4885ALDH1A1 2706/4885GAA 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.